WHO recommends dolutegravir as preferred HIV treatment option in all populations
Source: who.int Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir […]
Hard-to-reach populations 45% less likely to achieve optimal HIV treatment adherence
Source: avert.org Hard-to-reach populations living with HIV are 45% less likely to achieve optimal antiretroviral treatment (ART) adherence when compared […]